<DOC>
	<DOC>NCT00146211</DOC>
	<brief_summary>This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.</brief_summary>
	<brief_title>TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease</brief_title>
	<detailed_description>Multi-center, double blind, placebo-controlled study with parallel groups of outpatients with early, symptomatic Huntington's disease. Participants will be randomized to receive 1 gram twice daily (2 gram/day total daily dose) of active study drug or placebo. The 6-month placebo-controlled phased will be followed by a subsequent 6-month open-label extension phase with all subjects receiving 1 gram twice daily (2 grams/day total daily dose) of active study drug.</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Clinical features of Huntington's disease (HD) and confirmatory family history of HD, and/or CAG repeat expansion greater than or equal to 36 Ambulatory, not requiring skilled nursing care (total functional capacity [TFC] greater than or equal to 7) Chorea score of at least 2 in one extremity (UHDRS) Maximal dystonia less than or equal to 2 and maximal bradykinesia less than or equal to 2 35 years of age or older of either gender Must be on stable dosages of noncompetitive NMDA receptor antagonists, and/or antiepileptic medications for 60 days prior to baseline Females of childbearing potential must use adequate birth control History of established diagnosis of tardive dyskinesia Clinical evidence of unstable medical or psychiatric illness Clinically significant active and unstable psychotic disease (hallucinations or delusions) Major depression (Beck Depression Inventory [BDI]II Score greater than 20) at Screening Visit Suicidal ideation (BDIII item 9 greater than or equal to 2) at Screening Visit History of clinically significant substance abuse within 12 months of Baseline Visit Pregnant/lactating women Participation in other drug studies within 60 days prior to Baseline Visit Previous participation in any investigational study of ethylEPA (Miraxion™) Use of aspirin at daily dosage greater than 325 mg/day Exclusionary Drugs (within 6 months Baseline Visit): Depot neuroleptics Exclusionary Drugs (within 60 days Baseline Visit): Omega3 supplementation, tetrabenazine or reserpine, high dose and/or variable dose oral antipsychotic medications, steroid (other than topical), selenium supplements greater than 55 mcg/day, lithium, benzodiazepines (except for low dose), anticoagulants</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Trial</keyword>
	<keyword>ethyl-EPA</keyword>
	<keyword>Miraxion™</keyword>
	<keyword>treating</keyword>
	<keyword>mild</keyword>
	<keyword>moderate</keyword>
	<keyword>Huntington's</keyword>
</DOC>